The NICE lipid modification guideline, published in May this year, covered both primary and secondary prevention of CVD. This article will look briefly at the principles of this guideline in relation to primary prevention and then go further to highlight the key issues regarding statin prescribing for people established to be at high cardiovascular risk.
